

1 Determination of vancomycin exposure target and individualised dosing
2 recommendations for neonates: model-informed precision dosing

3 Zhe Tang^a, Jing Guan^a, Jingjing Li^b, Yanxia Yu^b, Miao Qian^c, Jiang Cao^a, Weiwei Shuai^a,
 4 Zheng Jiao^{d*}

5 ^a Department of Pharmacy, Women's Hospital of Nanjing Medical University, Nanjing
 6 Maternity and Child Health Care Hospital, Nanjing, China

7 ^b Department of Pharmacy, Suzhou Municipal Hospital, Suzhou, China

8 ^c Department of Neonatology, Women's Hospital of Nanjing Medical University, Nanjing
 9 Maternity and Child Health Care Hospital, Nanjing, China

10 ^d Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University,
 11 Shanghai, China

12

13 *Correspondence author

14 Zheng Jiao, jiaozhen@online.sh.cn

15 ORCID: 0000-0001-7999-7162

16 Tel/Fax: +86-021-22200000 ext 3021

17 Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University

18 241 Huai-hai West Road, 200030 Shanghai, China.

19 Abbreviations¹

¹ Abbreviations: AIC, Akaike information criteria; AKI, acute kidney injury; AUC, area under the concentration–time curve; BIC, Bayesian information criteria; CART, classification and regression tree; CI: confidence interval; CLCR, creatinine clearance; CV, coefficient of variation; cWT, current weight; ELBW, extremely-low-birth-weight; GA, gestational age; ICU, intensive care unit; MAPE, mean absolute prediction error; MC, Monte Carlo; MIC, minimum inhibitory concentration; MPE, mean prediction error; NBW, normal-birth-weight; NPDE, normalised prediction distribution error; NPV, negative predictive value; OFV, objective function value; PMA, postmenstrual age; PNA, postnatal age; Pop-PK/PD, population pharmacokinetic/pharmacodynamic; PPV, positive predictive value; ROC, receiver operating characteristic; SCR, serum creatinine; VAS, vasoactive drug.

20 **Highlights**

- 21 • The optimised neonatal exposure target of vancomycin was uniquely quantified
- 22 • Day 1 exposure of vancomycin is the predictor for clinical outcomes in neonates
- 23 • Vancomycin-induced acute kidney injury is not related to high exposure alone
- 24 • A lower exposure target is likely to be more effective for neonates than for adults
- 25 • Monte Carlo simulation provides a more suitable dosing regimen for neonates

26 Abstract

27 Few studies incorporating population pharmacokinetic/pharmacodynamic (Pop-PK/PD)
 28 modelling have been conducted to quantify the exposure target of vancomycin in neonates.
 29 To determine this target and dosing recommendations, a retrospective observational cohort
 30 study was established in neonates (chictr.org.cn, ChiCTR1900027919). A Pop-PK model
 31 was developed to estimate PK parameters. Causalities between acute kidney injury (AKI)
 32 occurrence and vancomycin use were verified using Naranjo criteria. Thresholds of
 33 vancomycin exposure in predicting AKI or efficacy were identified via classification and
 34 regression tree analysis. Associations between exposure thresholds and clinical outcomes
 35 including AKI and efficacy, were analysed by logistic regression. Dosing
 36 recommendations were designed using Monte Carlo (MC) simulations based on the
 37 optimised exposure target. Pop-PK modelling included 182 neonates with 411 observations.
 38 In covariate analysis, neonatal physiological maturation, renal function, and concomitant
 39 use of vasoactive drugs (VAS) significantly affected vancomycin pharmacokinetics. Seven
 40 cases of vancomycin-induced AKI were detected. Area under the concentration–time curve
 41 from 0–24 h (AUC_{0-24}) ≥ 485 mg·h/L was an independent risk factor for AKI after
 42 adjusting for VAS co-administration. Clinical efficacy of vancomycin was analysed in 42
 43 patients with blood culture-proven staphylococcal sepsis. AUC_{0-24} to minimum inhibitory
 44 concentration (AUC_{0-24}/MIC) ≥ 234 was the only significant predictor of clinical
 45 effectiveness. MC simulations indicated that regimens in Neonatal Formulary 7 and Red
 46 Book (2018) were not suitable for all neonates. In summary, AUC_{0-24} of 240–480 assuming
 47 MIC = 1 mg/L is a recommended exposure target of vancomycin in neonates. Model-
 48 informed dosing regimens are valuable in clinical practice.

49 **Key words:** vancomycin, neonate, pharmacokinetics, acute kidney injury, efficacy

1. Introduction

Neonates are predisposed to bacterial sepsis owing to their compromised immunity. *Staphylococcus aureus* and other *Staphylococcus* spp. are the predominant pathogenic bacteria[1]. Vancomycin is the first-line choice against staphylococcal sepsis for neonates in intensive care units (ICUs).

The recent consensus guideline[2] supports a Bayesian-derived area under the concentration–time curve to minimum inhibitory concentration (AUC/MIC) of 400 to 600 (assuming MIC=1 mg/L) as the vancomycin exposure target for adults infected by methicillin-resistant *S. aureus* (MRSA). Bayesian-derived AUC monitoring is advocated, whereas trough target-based dosing is not recommended, given that an identical trough value can be derived from a wide range of daily AUC values[2, 3].

Several published reports on adults have examined vancomycin exposure-outcome relationships by incorporating population pharmacokinetic/pharmacodynamic (Pop-PK/PD) modelling[4-9]. Comparatively, few exposure-outcome evaluations have been conducted in neonates[10]. Vancomycin is known as a potential nephrotoxin. However, its exposure threshold associated with vancomycin-induced acute kidney injury (AKI) has not been clearly defined in neonates[10]. The association between vancomycin exposure and clinical efficacy has not been clarified in this population either[11]. Thus, there is a critical need for clinical studies in neonates that associate individual exposure with clinical outcomes incorporating AKI and efficacy.

The aim of this study was to: (i) derive vancomycin exposure target that balances both AKI and efficacy in ICU neonates, with a focus on AUC/MIC; (ii) optimise neonatal dosing

recommendations of vancomycin using Monte Carlo (MC) simulation according to the exposure target obtained and the established Pop-PK model.

2. Patients and methods

2.1. Study population

A retrospective observational cohort study was conducted and executed in accordance with the recommendations of the Declaration of Helsinki (2000). The protocol was approved by the Ethics Committee of Nanjing Maternity and Child Health Care Hospital. The identities of patients were hidden during the study. Informed consent was approved unnecessary owing to the retrospective nature of the study. This study was registered at www.chictr.org.cn (ChiCTR1900027919).

The electronic medical records of patients who suffered from suspected or confirmed neonatal sepsis and received vancomycin treatment in the neonatal ICU from the 1st of January 2016 to the 31st of December 2019 were reviewed to determine eligibility. Clinical diagnosis of neonatal sepsis followed the criterion by Auriti et al[12]. Patients with postmenstrual age (PMA) \leq 48 weeks when vancomycin was initiated were included. All individuals had normal baseline serum creatinine (SCR) as defined by both gestational age (GA) and postnatal age (PNA) at the start of vancomycin treatment[13, 14]. They were treated with vancomycin for \geq 3 days, with at least one vancomycin serum concentration being monitored. The exclusion criteria included vancomycin serum concentrations lower than the limit of detection, a diagnosis of congenital anomalies of the kidney and urinary

tract, major congenital heart disease, or congenital haematological malignancy, and experience of AKI prior to vancomycin treatment.

Information of interest included: demographic information, dosing history, vancomycin serum concentration, SCR, creatinine clearance (CLCR), co-medications, clinical diagnosis, radiographic examinations, and microbiological culture. CLCR was calculated by the Schwartz equation[15] (Eq. 1).

$$\text{CLCR} [(\text{ml} \cdot \text{min}^{-1})/1.73\text{m}^2] = \frac{K \times \text{HT}(\text{cm}) \times 92.83}{\text{SCR}(\mu\text{mol/L}) + 10.79} \quad (\text{Eq. 1})$$

Where HT is body length of neonates, SCR is serum creatinine, and K is a constant equal to 0.33 (preterm neonates with PMA < 37 weeks) or 0.45 (term neonates with PMA ≥ 37 weeks).

According to the local protocol, neonates with suspected or confirmed sepsis received empirical therapy with vancomycin in combination with meropenem based on the presumptive diagnosis. Once a diagnosis was established, anti-infectives were rationalised to cover the causative pathogen.

Vancomycin (10–15 mg/kg; Vancocin, Lilly, S.A, Suzhou, China) was administered every 8 to 18 h with intermittent infusion lasting 60 min. Blood samples were collected 0.5 h before vancomycin administration (trough) or 0.5 h after infusion completion (peak) prior to the fourth or fifth dose. Target trough levels were 10 to 20 mg/L[16].

2.2. Bioanalytical method

Vancomycin concentrations were analysed by a fluorescence polarisation immunoassay using the ARCHITECT i2000SR (Abbott Laboratories, Chicago, IL, USA) within 24 h of

sample collection. The limit of detection was 1 mg/L, and the calibration range was 3 to 100 mg/L. The intra-day and inter-day coefficients of variation (CV) were less than 20%.

SCR was analysed using an enzymatic method (Beckman Coulter AU5800, Beckman Coulter Inc., Brea CA, USA) with linearity from 5 to 13275 $\mu\text{mol/L}$. The intra-day and inter-day CVs were less than 5%.

Etiological examinations were provided by the clinical laboratory of our hospital using the VITEK 2 microbial identification system (bioMérieux, Lyon, France). The broth microdilution (BMD) method was used to determine MICs. The interpretative reports were issued by laboratory technicians according to the criteria of The Clinical and Laboratory Standards Institute (CLSI)[17].

2.3. Pop-PK modelling

A Pop-PK model was developed to estimate PK parameters using nonlinear mixed effect modelling software Monolix (version 2019R2, Lixoft, France) with the Stochastic Approximation Expectation Maximization (SAEM) algorithm.

A one or two compartment model with first-order elimination was examined to fit the dataset. Interindividual variabilities in PK parameters were estimated using an exponential model. Residual unexplained variabilities were tested by an additive model, an exponential model, or a combined additive and exponential model. Potential covariates were screened, and concomitant medication present in less than 20% of the population was not tested.

Five models were employed to describe the impacts of size (weight) and maturation (age) on clearance (CL) (Table S1)[18-20]. The model with the lowest Akaike information

criteria (AIC) and Bayesian information criteria (BIC), as well as appropriate estimates of parameters, was employed for further analysis[21]. The selection of covariates was determined using a forward inclusion and a backward elimination process. Nested covariate models were statistically compared using a likelihood ratio test on differences in the objective function value (OFV). A reduction in OFV of 3.84 ($P < 0.05$) for forward inclusion and an increase in OFV of 6.63 ($P < 0.01$) for backward elimination were the criteria for retaining a covariate in the model.

The final model was internally assessed by visual inspection of goodness-of-fit plots, normalised prediction distribution error (NPDE), and bootstrap[21-23]. The data from a previous study by Li et al.[24] were used to validate the final model externally. The mean prediction error (MPE) and mean absolute prediction error (MAPE) (Table S2) were applied to calculate the bias and imprecision of model predictions[25].

2.4. Estimation of individual exposure variables

Individual exposure variables for the initial 48 h of vancomycin therapy, including day 1 AUC (AUC_{0-24}), day 2 AUC (AUC_{24-48}), and cumulative day 1 and 2 AUC (AUC_{0-48}), were estimated by Simulx (version 2019R2, Lixoft, France). Although there were no data on which AUC (i.e., initial AUC or AUC at steady state (AUC_{ss})) to use in determining the vancomycin exposure target, exposure to initial therapy may be more appropriate because the potential influence of the worsening of infection on vancomycin CL could be avoided. Further, the AUC in the first 48 h is critical for ICU neonates and has been associated with clinical outcomes in adults[9, 26].

2.5. Determination of the exposure target

2.5.1. AKI analysis

All patients were screened for AKI during vancomycin treatment. The definition of AKI included an increase in SCR of $\geq 26.5 \mu\text{mol/L}$ within 48 h, or ≥ 1.5 times from the previous lowest value within 7 days, or a urine volume $< 1.0 \text{ mL}/(\text{kg}\cdot\text{h})$ [27]. To identify whether the occurrence of AKI was related to the use of vancomycin, causality analyses were performed using the Naranjo criteria[28]. AKIs classified as definite, probable or possible by the Naranjo criteria, were considered to be vancomycin-induced side effects, and were eligible for further analyses. AKIs classified as doubtful were excluded from the study.

2.5.2. Efficacy analysis

The clinical efficacy was analysed for patients with blood culture-proven staphylococcal sepsis. Exclusion criteria were as follows: vancomycin treatment ≤ 5 days, polymicrobial infection or concomitant use of an antibiotic sensitive to the identified staphylococcus. Vancomycin treatment failure was defined as positive blood culture ≥ 5 days after the initiation of treatment, recurrence of bacteraemia within 30 days, or 30-day mortality[5, 7, 26].

Thresholds of vancomycin exposure in predicting AKI or efficacy were derived using classification and regression tree (CART) analysis (R package rpart, version 4.1-15). The predictive performance of thresholds, comprising CART-derived and other priori-defined ones, were evaluated using receiver operating characteristic (ROC) curves, along with predictive matrices including negative and positive predictive values (NPV and PPV, respectively) (R package pROC, version 1.16.2)[9, 29].

Logistic regression analyses were performed to quantify associations between vancomycin exposure and clinical outcomes. Other potential confounding variables with $P < 0.20$ in the univariate analysis were included in multivariate analyses using a stepwise approach and retained in the model. If multiple variables were correlated, only one was tested. P values of ≤ 0.05 were considered statistically significant.

According to the analyses of AKI and efficacy, the optimised exposure target was set as the basis for the following dosing regimen design.

2.6. Model-informed dosing regimen

Dosing regimens were designed and compared with the recommendations in Neonatal Formulary 7[30] and Red Book (2018)[31]. Virtual patients with different physiological characteristics were employed for MC simulations. Demographic information was obtained from the Fenton growth chart[32]. A total of 1000 replicates for each scenario were simulated to detect the most proper scheme (R package mlxR, version 2.0.2).

3. Results

3.1. Study population

One hundred and eighty-five neonates diagnosed with suspected or confirmed neonatal sepsis received intermittent intravenous infusion of vancomycin in our institution from the 1st of January 2016 to the 31st of December 2019. There were 182 patients eligible for this study, with 286 trough and 125 peak concentrations (Table S3). Two patients with

incomplete data and one patient diagnosed with haematological malignancy were excluded (Fig. 1).

3.2. Pop-PK modelling

A Pop-PK model was developed to estimate individual parameters. A one compartment model with first-order elimination was sufficient to fit the data. A proportional model was chosen to describe residual unexplained variabilities. The detailed modelling process is summarised in Table S4.

Both, Model II with PMA, and Model III had relatively lower AIC and BIC. Model II with PMA was selected because of its simplicity. SCR, CLCR, and the co-administration of vasoactive drugs (VAS) were recognised as significant covariates on CL. As SCR and CLCR were correlated and performed equally, SCR was retained owing to better clinical accessibility. A 14% decrease in CL was associated with the co-administration of VAS. Moreover, current weight (cWT) was incorporated into the volume of distribution (V) for physiological plausibility. The results of the final model are listed in Table 1.

The goodness-of-fit plot of the final model showed no obvious bias or trend (Fig. 2). The results of NPDE generally satisfied the hypothesis of normal distribution (Fig. 3). Bootstrap analysis (n = 2000) showed that the final model was precise, because the median parameter estimates were close to those of the final model (Table 1).

In the external evaluation, 28 patients in an earlier study by Li et al.[24] were included. All observations were troughs. The medians for cWT, PMA, and SCR were 1.66 kg (range, 0.80 to 2.52 kg), 33.22 weeks (range, 28.28 to 36.71 weeks), and 35.42 $\mu\text{mol/L}$ (range, 14.17 to 51.71 $\mu\text{mol/L}$), respectively. No one was co-medicated with VAS. The MPE and

MAPE for the final model were 3.97% (standard deviation, 19.88%) and 13.01% (standard deviation, 15.36%), respectively.

As the external evaluation showed no obvious bias, we combined all data to re-estimate the PK parameters. The estimates did not show an apparent difference (Table S5).

3.3. Determination of the exposure target

3.3.1 AKI analysis

Seven AKI cases were identified in total. Five occurred on day 3 after vancomycin was initiated, and two on day 4. Patients who experienced AKI had higher baseline SCR and lower CLCR than those who did not experience AKI. Although there was no statistical difference in daily dose between patients with and without AKI, patients with AKI had significantly higher vancomycin exposure quantified by AUC_{0-24} , AUC_{24-48} , and AUC_{0-48} owing to their decreased vancomycin CL. (Table 2).

With regard to the causality between AKI occurrence and the use of vancomycin, causalities for four cases were classified as probable, and three cases as possible using the Naranjo criteria. Hence, all AKI cases were eligible for the following analyses. Vancomycin dosages were immediately reduced for six patients after AKI occurrences. Then their AKI symptoms were alleviated, and renal function recovered within 5 days.

VAS, prescribed to 39 patients, was the major potential nephrotoxin besides vancomycin. VAS refers to milrinone, dopamine, epinephrine, and norepinephrine in our institution. Six of seven AKI cases were co-administered VAS.

In ROC curve analysis, AUC_{0-24} , AUC_{24-48} , and AUC_{0-48} significantly predicted AKI with good performance (Fig. 4A). The CART-derived threshold of $AUC_{0-24} \geq 485$ mg·h/L had the highest predictive value with an area under the ROC curve (AUC_{ROC}) of 0.74 (confidence interval (CI): 0.54, 0.94) (Table S6). PPV, which represented true-positive predictions of patients who experienced AKI, was positively correlated with vancomycin exposure. At $AUC_{0-24} \geq 485$ mg·h/L, PPV increased more rapidly, indicating an additional risk of AKI (Table S6). Therefore, this threshold was included in further multivariate regression analyses.

In univariate regression analysis, PNA, persistent pulmonary hypertension of newborn, and concomitant use of VAS or furosemide were identified as potential confounding factors that influenced AKI besides AUC_{0-24} (Table S7). The vancomycin trough was not included in multivariate analysis because it was strongly correlated with AUC_{0-24} (Spearman coefficient = 0.75, $P < 0.01$). SCR and CLCR were also excluded as they were included in the diagnostic criteria for AKI. In multivariate regression analysis, $AUC_{0-24} \geq 485$ mg·h/L was independently associated with AKI after adjusting for the concomitant use of VAS (Table 3).

3.3.2 Efficacy analysis

Seventy-nine patients had positive blood cultures. Thirty-one with blood culture-proven non-staphylococcal sepsis, four with polymicrobial infections, and two with co-administration of an antimicrobial that affected the identified staphylococcal species were excluded. Forty-two patients with blood culture-proven staphylococcal sepsis were eligible

for efficacy analysis (Fig. 1). Sixteen of them were infected by *S. aureus*, whereas the others were infected by other *Staphylococcus* spp.

Seven patients experienced treatment failures. Three died during vancomycin treatment. Four had positive blood culture results ≥ 5 days after the initiation of vancomycin, and linezolid was used as an alternative. No one experienced a recurrence of bacteraemia. Despite the insignificant difference in daily dosage and MICs between patients with and without effective treatment, vancomycin exposures were much lower among ineffective patients quantified by AUC_{0-24}/MIC , AUC_{24-48}/MIC , and AUC_{0-48}/MIC (Table 2).

ROC analyses showed that AUC_{0-24}/MIC , AUC_{24-48}/MIC and AUC_{0-48}/MIC performed well in the prediction of efficacy (Fig. 4B). The threshold of $AUC_{0-24}/MIC \geq 234$ had the highest predictive value with an AUC_{ROC} of 0.86 (CI: 0.71, 1.00) (Table S8). NPV, which referred to true-negative predictions of patients who experienced treatment failure, was negatively correlated with vancomycin exposure. At $AUC_{0-24}/MIC \geq 234$, PPV remained low, indicating a decreased risk of treatment failure (Table S8), which is why this threshold was included in further analyses.

Birth weight and cWT were identified as potential confounding factors that influenced efficacy, besides AUC_{0-24}/MIC , by univariate regression analysis (Table S7). These two variables were apparently correlated. cWT was included in multivariate analyses because it better reflected the actual physiological status during vancomycin treatment. In multivariate regression analysis, $AUC_{0-24}/MIC \geq 234$ was the only significant factor associated with efficacy (Table 3).

MIC distributions from The European Committee on Antimicrobial Susceptibility Testing (EUCAST) show that 75% of *S. aureus* isolates and 45% of other *Staphylococcus* spp. isolates have a MIC of 1 mg/L to vancomycin[33]. According to analyses above, when MIC > 1 mg/L, the probability of achieving the exposure threshold for efficacy ($AUC_{0-24}/MIC \geq 234$) was low as the exposure was lower than the threshold for AKI ($AUC_{0-24} \geq 485$). Therefore, the optimised exposure target for vancomycin in neonates was set as an AUC_{0-24} of 240 to 480, assuming MIC = 1 mg/L.

3.4. Model-informed dosing regimen

The dosage recommendations by the references[30, 31] and this study are presented in Table S9 and Table 4 respectively.

Generally, patients with concomitant use of VAS requires a reduced daily dose. The dosing interval of 24 h is suitable for extremely preterm patients (PMA < 28 weeks), with a dose of 12.5–20 mg/kg. For preterm patients with a PMA between 28 and 36 weeks, proper dosing intervals varies from 12 to 24 h. Term neonates (PMA \geq 37 weeks) require dosing intervals between 8 and 12 h. Dosing intervals \leq 8 h are not necessary.

Our results suggest that the daily dose for extremely-low-birth-weight (ELBW) neonates (cWT < 1 kg) is 12.5 to 20 mg/kg (Table 4). However, Neonatal Formulary 7[30] recommends a daily dose of 20 mg/kg for all ELBW neonates. The maximum daily dose recommended by Red Book (2018)[31] for these patients is 30 mg/kg. Quite a few of ELBW neonates are overdosed in these references. Table 4 also shows that a daily dose of 20 to 45 mg/kg is required for normal-birth-weight (NBW) neonates with cWT > 2.7 kg and SCR \leq 60 μ mol/L, whereas Red Book (2018)[31] suggests a daily dose of 30 mg/kg

for patients (GA > 28 week) with normal renal function (SCR < 61.7 $\mu\text{mol/L}$). Apparently, this regimen is unable to satisfy the treatment needs of all NBW neonates.

4. Discussion

To the best of our knowledge, this is the first study in neonates uniquely utilising Pop-PK/PD modelling with Bayesian estimation to evaluate vancomycin exposure associated with clinical outcomes including AKI and efficacy. With Bayesian estimation, PK/PD variability for vancomycin exposure-outcomes evaluations can be plausibly quantified. Bayesian estimation also allows for more accurate and reliable quantification of exposure parameters (i.e. AUC) with sparse data. Moreover, using Pop-PK based on MC simulations, dosing recommendations for neonates can be derived based on the optimised exposure target.

The exposure threshold for vancomycin-induced AKI in neonates has been clearly defined in this study for the first time. The threshold for AKI, AUC_{0-24} of 480 $\text{mg}\cdot\text{h/L}$, is lower than that in previous report on children. Le et al.[34] suggests that AUC_{ss} over 24 h in children should be less than 800 $\text{mg}\cdot\text{h/L}$ to minimise AKI risk. The time to AKI in Le's study ranged from 1 to 15 days[34]. The reported threshold based on AUC_{ss} is probably inapplicable in clinical practice because AKI may occur prior to a steady state. The AUC after the occurrence of AKI is an inappropriate predictor for AKI because high exposure is not the cause of AKI, but the consequence.

In this study, the renal function of six of seven patients with AKI recovered after a reduction in the vancomycin dosage, although they were under a high vancomycin

exposure when AKI occurred. The results of causality analyses imply that an elevated exposure of vancomycin is likely to be a risk factor pertinent to AKI occurrence. In addition, neonates may be tolerant to high vancomycin exposure temporarily and vancomycin-induced renal impairments are possibly reversible. The ongoing monitoring of both vancomycin serum concentrations and renal function needs to be emphasised in clinical practice.

Our study reveals that the concomitant use of VAS is not only a significant covariate on vancomycin CL, but also a confounding factor in predicting AKI. Six of seven patients who experienced AKI were co-medicated with VAS. Given that VAS has been reported as an independent risk factor for the development of AKI among ICU neonates[35], vancomycin-induced AKI is probably not only associated with vancomycin exposure alone[2, 8, 9, 36]. Multivariate regression analyses show that high vancomycin exposure ($AUC_{0-24} \geq 485 \text{ mg}\cdot\text{h/L}$) remains an independent predictor of AKI after adjusting for the concomitant use of VAS. Although our study cannot explain whether the threshold for AKI will change as a result of concomitant VAS use, there is reason to believe high vancomycin exposure in addition to VAS application contributes to the occurrence of AKI.

The threshold in predicting efficacy in our study ($AUC_{0-24}/MIC \geq 234$) is far below that in some previous studies in adults (Casapao et al.: $AUC_{0-24}/MIC \geq 600$; Song et al.: AUC_{ss} over 24 h/ $MIC \geq 393$)[6, 7]. However, research by Padari et al. showed that an AUC/MIC of ≥ 300 or ≥ 400 does not improve clinical effectiveness in neonates with staphylococcal sepsis[11]. This indicates that a relatively low exposure ($AUC/MIC < 300$) may still be effective for neonates. In the absence of other efficacy data in neonates to clarify the

AUC/MIC necessary for clinical effectiveness against staphylococcal sepsis, the threshold for efficacy needs to be validated in the future.

The relationship between vancomycin exposure and clinical efficacy had not been discovered in previous paediatric and neonatal studies[11, 37]. In contrast, we found that $AUC_{0-24}/MIC \geq 234$ was strongly correlated with efficacy. This disparity may be caused by several factors. Primarily, the previous study by Hahn et al.[37] focused on patients with various sites of infection, whereas all patients in our study had bloodstream infections. Considering several breakpoints reported by studies on different infectious diseases in adults[4-7], the threshold of vancomycin exposure may be infection site-dependent. Secondly, the whole population of the previous study by Padari et al.[11] had a relatively low vancomycin exposure with only 12% of patients achieving $AUC/MIC \geq 400$ compared with 26% in our study. The correlation between efficacy and AUC/MIC may not be detected owing to AUC/MIC values concentrated within a narrow range.

In contrast to the regimen designed in this study, dose recommendations in current referential books are unsuitable for all neonates. The scheme of Neonatal Formulary 7[30] is merely PMA-based, whereas the regimen of Red Book (2018)[31] is based on GA and SCR. According to our Pop-PK model, renal function and the concomitant use of VAS are significant covariates on CL and must be considered in regimen design. Furthermore, regimens in both references[30, 31] are overdosed to ELBW neonates, and the regimen of Red Book (2018)[31] is inadequate for NBW neonates with normal renal function.

There are several limitations to our study. Firstly, our data were derived from a homogeneous neonatal population who had bloodstream infections and were administered

370 vancomycin with intermittent infusion. Therefore, the optimised exposure target should be
 371 extrapolated to other populations, who may have different infection sites, with caution.
 372 Secondly, given the low morbidity of vancomycin-induced AKI[38] and high effective rate
 373 of staphylococcal sepsis in neonates[2, 39], it is important to recognise that the optimised
 374 exposure target has limited ability to predict AKI or efficacy. This target can only serve as
 375 a guide that balances AKI and efficacy[9]. Finally, the sample size of this study was
 376 relatively small. Our findings need to be validated further in large multi-centred
 377 prospective studies.

378 In conclusion, the exposure target of AUC_{0-24} of 240 to 480 (assuming $MIC = 1 \text{ mg/L}$)
 379 should be advocated to achieve clinical efficacy while minimising side effects for
 380 vancomycin treatment in neonates. Model-informed dosing regimens are valuable in
 381 clinical practice for ICU neonates with staphylococcal sepsis.

Acknowledgements

We thank Dr Xiaohui Chen and other paediatricians from neonatal ICU of Nanjing Maternity and Child Health Care Hospital. We are also grateful to Dr Xiaojun Ji (Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Nanjing, China) for his assistance with figure preparation.

Funding: This work was supported by the Hospital Pharmacy Foundation of Nanjing Pharmaceutical Association (grant number: 2019YX004). The funding source was not involved in any process of this study.

Declaration of interests: none.

Ethical approval: The study was approved by the Ethics Committee of Nanjing Maternity and Child Health Care Hospital (Nanjing, P.R China) according to the Declaration of Helsinki.

Contributors

Conception and design of the study: Z.T., Z.J.

Acquisition of data: J.G., WW.S., JJ.L., YX.Y.

Analysis of data: Z.T., J.C.

402 Interpretation of data: Z.T., M.Q.

403 Drafting and revising the manuscript: Z.T., Z.J.

404 Revising the manuscript for important intellectual content and final approval of the version
405 for publication: All authors.

406

407 **Appendix. Supplementary data**

408 Tables S1 to S9 are available as Supplementary data in the online version.

References

- [1] Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker JN. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. *Semin Fetal Neonatal Med.* 2013;18:28-34. <https://doi.org/10.1016/j.siny.2012.10.003>.
- [2] Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm.* 2020;77:835-64. <https://doi.org/10.1093/ajhp/zxaa036>.
- [3] Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. *Clin Infect Dis.* 2011;52:969-74. <https://doi.org/10.1093/cid/cir078>.
- [4] Brown J, Brown K, Forrest A. Vancomycin AUC₂₄/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant *Staphylococcus aureus* and its association with attributable mortality during hospitalization. *Antimicrob Agents Chemother.* 2012;56:634-8. <https://doi.org/10.1128/aac.05609-11>.
- [5] Gawronski KM, Goff DA, Jack B, Khadem TM, Bauer KA. A Stewardship Program's Retrospective Evaluation of Vancomycin AUC₂₄/MIC and Time to Microbiological Clearance in Patients with Methicillin-Resistant *Staphylococcus aureus* Bacteremia and Osteomyelitis. *Clin Ther.* 2013;35:772-9. <https://doi.org/10.1016/j.clinthera.2013.05.008>.
- [6] Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, et al. Association between vancomycin day 1 exposure profile and outcomes among patients with

432 methicillin-resistant *Staphylococcus aureus* infective endocarditis. *Antimicrob Agents*
433 *Chemother.* 2015;59:2978-85. <https://doi.org/10.1128/AAC.03970-14>.

434 [7] Song KH, Kim HB, Kim HS, Lee MJ, Jung Y, Kim G, et al. Impact of area under the
435 concentration-time curve to minimum inhibitory concentration ratio on vancomycin
436 treatment outcomes in methicillin-resistant *Staphylococcus aureus* bacteraemia. *Int J*
437 *Antimicrob Agents.* 2015;46:689-95. <https://doi.org/10.1016/j.ijantimicag.2015.09.010>.

438 [8] Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ. Establishment of an AUC
439 0–24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for
440 Methicillin-Resistant *Staphylococcus aureus* Bacteremia. *Antimicrob Agents Chemother.*
441 2017;61: e02535-16. <https://doi.org/10.1128/aac.02535-16>.

442 [9] Zasowski EJ, Murray KP, Trinh TD, Finch NA, Pogue JM, Mynatt RP, et al.
443 Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients
444 Receiving Intravenous Vancomycin. *Antimicrob Agents Chemother.* 2018;62:e01684-17.
445 <https://doi.org/10.1128/aac.01684-17>.

446 [10] Jacqz-Aigrain E, Leroux S, Zhao W, van den Anker JN, Sharland M. How to use
447 vancomycin optimally in neonates: remaining questions. *Expert Rev Clin Pharmacol.*
448 2015;8:635-48. <https://doi.org/10.1586/17512433.2015.1060124>.

449 [11] Padari H, Oselin K, Tasa T, Metsvaht T, Loivukene K, Lutsar I. Coagulase negative
450 staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? *BMC*
451 *Pediatr.* 2016;16:206. <https://doi.org/10.1186/s12887-016-0753-0>.

452 [12] Auriti C, Ronchetti M, Pezzotti P, Marrocco G, Quondamcarlo A, Seganti G, et al.
453 Determinants of nosocomial infection in 6 neonatal intensive care units: an Italian

454 multicenter prospective cohort study. Infection control and hospital epidemiology.
455 2010;31:926-33. <https://doi.org/10.1086/655461>.

456 [13] Boer D, de Rijke Y, Hop W, Cransberg K, Dorresteyn E. Reference values for serum
457 creatinine in children younger than 1 year of age. Pediatric nephrology (Berlin, Germany).
458 2010;25:2107-13. <https://doi.org/10.1007/s00467-010-1533-y>.

459 [14] Bateman D, Thomas W, Parravicini E, Polesana E, Locatelli C, Lorenz J. Serum
460 creatinine concentration in very-low-birth-weight infants from birth to 34-36 wk
461 postmenstrual age. Pediatric research. 2015;77:696-702.
462 <https://doi.org/10.1038/pr.2015.25>.

463 [15] Schwartz GJ, Brion LP, Spitzer A. The Use of Plasma Creatinine Concentration for
464 Estimating Glomerular Filtration Rate in Infants, Children, and Adolescents. Pediatric
465 Clinics of North America. 1987;34:571-90. [https://doi.org/10.1016/s0031-3955\(16\)36251-](https://doi.org/10.1016/s0031-3955(16)36251-4)
466 4.

467 [16] Ye ZK, Chen YL, Chen K, Zhang XL, Du GH, He B, et al. Therapeutic drug
468 monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring,
469 Chinese Pharmacological Society. J Antimicrob Chemother. 2016;71:3020-5.
470 <https://doi.org/10.1093/jac/dkw254>.

471 [17] CLSI. Performance Standards for Antimicrobial Susceptibility Testing. CLSI
472 supplement M100. 30 ed. Pennsylvania, USA: Wayne; 2020, p. 58-9.

473 [18] Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults.
474 J Pharm Sci. 2013;102:2941-52. <https://doi.org/10.1002/jps.23574>.

475 [19] Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, et al. A Population Pharmacokinetic
476 Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear

477 Pharmacokinetic Model Based on Protein-Binding Saturation. Clin Pharmacokinet.
478 2014;54:305-17. <https://doi.org/10.1007/s40262-014-0212-8>.

479 [20] Li ZL, Liu YX, Jiao Z, Qiu G, Huang JQ, Xiao YB, et al. Population Pharmacokinetics
480 of Vancomycin in Chinese ICU Neonates: Initial Dosage Recommendations. Front
481 Pharmacol. 2018;9:603. <https://doi.org/10.3389/fphar.2018.00603>.

482 [21] Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, et al. Establishing Best
483 Practices and Guidance in Population Modeling: An Experience With an Internal
484 Population Pharmacokinetic Analysis Guidance. CPT Pharmacometrics Syst Pharmacol.
485 2013;2:e51. <https://doi.org/10.1038/psp.2013.26>.

486 [22] Ette EI. Stability and performance of a population pharmacokinetic model. J Clin
487 Pharmacol. 1997;37:486-95. <https://doi.org/10.1002/j.1552-4604.1997.tb04326.x>.

488 [23] Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors
489 to evaluate nonlinear mixed-effect models: The npde add-on package for R. Comput
490 Methods Programs Biomed. 2008;90:154-66. <https://doi.org/10.1016/j.cmpb.2007.12.002>.

491 [24] Li JJ, Liu YX, Tang L, Weng XH, Wang SN, Jiao Z, et al. Population
492 Pharmacokinetics of Vancomycin in Chinese Neonates. Chin Pharm J. 2017;52:1434-41.
493 <https://doi.org/10.11669/cpj.2017.16.012>.

494 [25] van der Meer AF, Marcus M, Touw DJ, Proost JH, Neef C. Optimal Sampling Strategy
495 Development Methodology Using Maximum A Posteriori Bayesian Estimation. Ther Drug
496 Monit. 2011;33:133-46.

497 [26] Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, et al.
498 Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus

499 bloodstream infections: how much is enough? Clin Infect Dis. 2014;59:666-75.
500 <https://doi.org/10.1093/cid/ciu398>.

501 [27] Jetton J, Boohaker L, Sethi S, Wazir S, Rohatgi S, Soranno D, et al. Incidence and
502 outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational,
503 observational cohort study. The Lancet Child & adolescent health. 2017;1:184-94.
504 [https://doi.org/10.1016/s2352-4642\(17\)30069-x](https://doi.org/10.1016/s2352-4642(17)30069-x).

505 [28] Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E, et al. A method for
506 estimating the probability of adverse drug reactions. Clinical pharmacology and
507 therapeutics. 1981;30:239-45. <https://doi.org/10.1038/clpt.1981.154>.

508 [29] Rhodes NJ, O'Donnell JN, Lizza BD, McLaughlin MM, Esterly JS, Scheetz MH. Tree-
509 Based Models for Predicting Mortality in Gram-Negative Bacteremia: Avoid Putting the
510 CART before the Horse. Antimicrob Agents Chemother. 2016;60:838-44.
511 <https://doi.org/10.1128/aac.01564-15>.

512 [30] Ainsworth SB. Neonatal Formulary 7: Drug Use in Pregnancy and the First Year of
513 Life. 7th ed. UK: Wiley Blackwell. BMJ.; 2014, p. 520.

514 [31] Pediatrics AAo. Red Book: Report of the Committee on Infectious Diseases. In:
515 Kimberlin DW BM, Jackson MA, Long SS, editor. Thirty-first ed. USA: Itasca, IL:
516 American Academy of Pediatrics; 2018, p. 918.

517 [32] Fenton TR, Sauve RS. Using the LMS method to calculate z-scores for the Fenton
518 preterm infant growth chart. Eur J Clin Nutr. 2007;61:1380-5.
519 <https://doi.org/10.1038/sj.ejcn.1602667>.

520 [33] EUCAST. Antimicrobial wild type distributions of microorganisms,
521 <https://mic.eucast.org/Eucast2/SearchController/search.jsp?action=performSearch&Begin>

522 Index=0&Micdif=mic&NumberIndex=50&Antib=-1&Specium=15; 2020 [accessed 2
523 September 2020].

524 [34] Le J, Ny P, Capparelli E, Lane J, Ngu B, Muus R, et al. Pharmacodynamic
525 Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children. J
526 Pediatric Infect Dis Soc. 2015;4:e109-e16. <https://doi.org/10.1093/jpids/piu110>.

527 [35] Stojanovic V, Barisic N, Milanovic B, Doronjski A. Acute kidney injury in preterm
528 infants admitted to a neonatal intensive care unit. Pediatr Nephrol. 2014;29:2213-20.
529 <https://doi.org/10.1007/s00467-014-2837-0>.

530 [36] Sinclair EA, Yenokyan G, McMunn A, Fadrowski JJ, Milstone AM, Lee CK. Factors
531 associated with acute kidney injury in children receiving vancomycin. Ann Pharmacother.
532 2014;48:1555-62. <https://doi.org/10.1177/1060028014549185>.

533 [37] Hahn A, Frenck RW, Allen-Staat M, Zou Y, Vinks AA. Evaluation of Target
534 Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant
535 Staphylococcus Aureus Bacteremia. Ther Drug Monit. 2015;37:619-25.
536 <https://doi.org/10.1097/ftd.0000000000000190>.

537 [38] Lestner JM, Hill LF, Heath PT, Sharland M. Vancomycin toxicity in neonates: a
538 review of the evidence. Curr Opin Infect Dis. 2016;29:237-47.
539 <https://doi.org/10.1097/QCO.0000000000000263>.

540 [39] Wang J, Zhang H, Yan J, Zhang T. Literature review on the distribution characteristics
541 and antimicrobial resistance of bacterial pathogens in neonatal sepsis. J Matern Fetal
542 Neonatal Med. 2020:1-10. <https://doi.org/10.1080/14767058.2020.1732342>.

543 **Figures**

544 **Fig. 1.** Study flow.

545 **Fig. 2.** Goodness-of-fit plot of the final established Pop-PK model.


546 (A) Population predictions vs. observations. (B) Individual predictions (IPRED) vs.
547 observations. The black solid lines are the reference lines, and black dashed lines are the
548 loess smooth lines.


549 **Fig. 3.** Normalized prediction distribution error (NPDE) plots for the final model.

550 (A) Histogram of NPDE values; (B) NPDE vs. the probability density. Black dashed lines,
551 theoretical distribution. Blue dashed line, empirical distribution. (C) Scatter plot of the time
552 vs. NPDE; (D) Scatterplot of serum concentrations (Cc) vs. NPDE. Blue filled dots,
553 observed data; Black dashed lines, theoretical mean; Blue solid lines, empirical percentiles
554 of observations; Blue-shaded area, 95% confidence interval (CI) for the 5th and 95th
555 percentiles of the predicted values. Pink-shaded area, 95% CI for the 50th percentiles of
556 the predicted values; Red-shaded area, outliers.


557 **Fig. 4.** Receiver operating characteristic (ROC) curves.

558 (A) ROC curves of AUC_{0-24} , AUC_{24-48} and AUC_{0-48} for prediction of AKI. (B) ROC curves
559 of AUC_{0-24}/MIC , AUC_{24-48}/MIC and AUC_{0-48}/MIC for prediction of efficacy. AUC, area
560 under the concentration–time curve; MIC, minimum inhibitory concentration; AUC_{ROC} ,
561 area under the ROC curve.






563



564



565

566 Tables

567 Table 1

568 The estimates of the final model and 2000 bootstrap results.

Parameter ^a	Final model		Bootstrap		Bias (%) ^c
	Estimate	RSE (%) ^b	Median	2.5%–97.5%	
Structure model parameter					
V _{pop} (L)	0.86	3.02	0.87	0.80 – 0.93	0.82
CL _{pop} (L/h)	0.09	2.11	0.09	0.08 – 0.09	0.69
beta1	2.35	1.20	2.29	1.94 – 2.66	–2.77
beta2	0.18	3.41	0.18	0.09 – 0.28	4.55
F _{VAS}	0.86	0.34	0.85	0.77 – 0.94	–1.28
Inter-individual variability					
V (%CV)	11%	24.20	14%	0.09 – 0.20	24.11
CL (%CV)	24%	6.85	23%	0.20 – 0.26	–2.11
Residual variability					
Proportional (%CV)	0.21	4.82	0.21	0.18 – 0.24	–0.47

569 $V = V_{pop} \times \left(\frac{cWT}{1.5}\right)$

570 $CL = CL_{pop} \times \left(\frac{cWT}{1.5}\right)^{0.75} \times \left(\frac{PMA}{32}\right)^{beta1} \times \left(\frac{30}{SCR}\right)^{beta2} \times F_{VAS}$

571 V_{pop}, population mean estimate for volume of distribution in a subject with a body weight
 572 of 1.5 kg; cWT, current body weight; CL_{pop}, population mean estimate for vancomycin
 573 clearance in a subject with a body weight of 1.5 kg; PMA, postmenstrual age; SCR, serum
 574 creatinine; F_{VAS}, scaling factor of concomitant use of vasoactive drugs.

575 ^aV (%CV), interindividual variability of volume of distribution; CL (%CV), interindividual
 576 variability of vancomycin clearance.

577 ^bRSE, relative standard error.

578 ^cBias%, relative bias of estimates by Monolix to the median estimates by 2000 bootstrap
 579 procedures. The rate of bias in fixed effects less than 5% was thought acceptable. It was
 580 calculated by the formula $Bias(\%) = (Median_{bootstrap} - Median_{final\ model})/Median_{final\ model} \times 100\%$.
 581

582 **Table 2**

583 Comparisons of demographic and PK/PD characteristics between patients with and without AKI / patients with and without effective
584 treatment.

	Non-AKI ^d patients (N=175) median (range/proportion)	AKI patients (N=7) median (range/proportion)	P*	Effective patients (N=35) median (range/proportion)	Ineffective patients (N=7) median (range/proportion)	P*
Maturation						
Gender	98/77(male/female)	4/3(male/female)	1.00	18/17(male/female)	5/2(male/female)	0.43
Gestational age (weeks)	30.43(22.29–41.29)	33.86(24.71–40.00)	0.20	31.00(24.43–40.00)	29.71(26.29–33.29)	0.32
Postnatal age (weeks)	1.71(0.14–12.43)	0.29(0.43–1.71)	<0.01	2.14 (0.43–4.86)	2.29 (0.57–3.71)	1.00
Postmenstrual age (weeks)	33.00(22.29–44.43)	34.00(26.29–40.57)	0.66	33.14(26.00–40.71)	32.14(26.71–34.43)	0.41
Birth weight (kg)	1.35(0.55–4.40)	1.74(0.77–3.05)	0.43	1.37(0.70–3.03)	0.95(0.77–1.18)	< 0.01
Current weight (kg)	1.54(0.55–5.57)	1.77(0.90–3.02)	0.71	1.50(0.78–2.98)	1.18(0.74–1.45)	< 0.01
Renal Function						
Baseline serum creatinine (μmol/L)	28.20(3.90–77.50)	45.70(32.80–75.80)	<0.01	24.30(9.60–55.21)	22.80(10.70–44.40)	0.84
Creatinine clearance [(mL/min)/1.73m ²]	33.53(9.69–142.18)	24.60(15.01–29.97)	<0.05	38.40(17.55–81.95)	36.71(22.37–51.40)	0.60
PK/PD Parameters						
Daily dose (mg/kg)	29.79(12.96–62.07)	28.80(11.41–46.69)	0.28	29.68(16.25–45.30)	29.55(18.92–45.52)	0.65
Clearance [L/(h·kg)]	0.07(0.02–0.16)	0.03(0.03–0.04)	<0.01	0.06(0.04 – 0.16)	0.06(0.05 – 0.13)	0.77

Vancomycin trough (mg/L)	10.67(3.11–33.01)	23.50(13.88–51.36)	<0.01	10.76(3.14–23.98)	9.72(6.42–12.76)	0.22
AUC _{0–24} (mg·h/L) ^a	360(191–617)	489(270–788)	0.08	366(212–597)	285(238–412)	< 0.05
AUC _{24–48} (mg·h/L)	531(265–978)	623(389–1066)	0.12	565(309–978)	436(320–546)	< 0.05
AUC _{0–48} (mg·h/L)	891(456–1575)	1112(659–1854)	0.11	928(520–1575)	721(557–899)	<0.05
AUC _{0–24} ≥485(mg·h/L)	17 (9.71%)	4 (57.1%)	<0.01	/	/	/
AUC _{24–48} ≥622(mg·h/L)	42 (24.0%)	4 (57.1%)	0.07	/	/	/
AUC _{0–48} ≥1077(mg·h/L)	36 (20.6%)	4 (57.1%)	<0.05	/	/	/
MIC (mg/L) ^b	/	/	/	2.0 (0.5–2.0)	2.0 (2.0–2.0)	0.12
AUC _{0–24} /MIC≥234	/	/	/	30 (85.7%)	1 (14.3%)	<0.01
AUC _{24–48} /MIC≥278	/	/	/	22 (62.9%)	0 (0.00%)	<0.01
AUC _{0–48} /MIC≥450	/	/	/	23 (65.7%)	0 (0.00%)	<0.01
Comorbidities						
Patent ductus arteriosus	76 (43.4%)	7 (100.0%)	<0.01	10 (28.6%)	3 (42.9%)	0.66
Pneumonia	74 (42.3%)	4 (57.1%)	0.46	8 (22.9%)	3 (42.9%)	0.35
Bronchopulmonary dysplasia	41 (23.4%)	2 (28.6%)	0.67	5 (14.3%)	2 (28.6%)	0.58
Meningitis	36 (20.6%)	1 (14.3%)	1.00	4 (11.4%)	0 (0.00%)	1.00
Neonatal necrotic enterocolitis	31 (17.7%)	2 (28.6%)	0.61	5 (14.3%)	0 (0.00%)	0.57
Persistent pulmonary hypertension of newborn	14 (8.00%)	2 (28.6%)	0.12	2 (5.71%)	0 (0.00%)	1.00
Co-medication						
Meropenem	82 (46.9%)	7 (100.0%)	<0.01	11 (31.4%)	2 (28.6%)	1.00
Vasoactive drugs ^c	33 (18.9%)	6 (85.7%)	<0.01	2 (5.71%)	1 (14.3%)	0.43
Furosemide	26 (14.9%)	4 (57.1%)	<0.05	1 (2.86%)	1 (14.3%)	0.31

	Ibuprofen	8 (4.57%)	0 (0.00%)	1.00	1 (2.86%)	0 (0.00%)	1.00
	Outcome						
	30-day mortality	13 (7.43%)	1 (14.3%)	0.39	0 (0.00%)	3 (42.9%)	< 0.01
585	*Continuous variables were compared by Mann–Whitney U tests, and dichotomous variables by Fisher exact tests.						
586	^a AUC, area under the concentration–time curve.						
587	^b MIC, minimum inhibitory concentration.						
588	^c Vasoactive drugs, which are referred to milrinone, dopamine, epinephrine, and norepinephrine in our institution.						
589	^d AKI, acute kidney injury.						

590 Table 3

591 Results of multivariate regression analysis.

Variable ^a	adjusted odds ratio (95% CI) ^b	P
AKI analysis		
AUC ₀₋₂₄ ≥ 485 (mg·h/L)	11.31 (1.95,65.54)	<0.01
Concomitant use of VAS	24.23 (2.65,221.76)	<0.01
Efficacy analysis		
AUC ₀₋₂₄ /MIC ≥ 234	36 (3.54,365.98)	<0.01

592 ^a AUC, area under the concentration–time curve; MIC, minimum inhibitory concentration;
 593 VAS, vasoactive drugs, which are referred to milrinone, dopamine, epinephrine, and
 594 norepinephrine in our institution.

595 ^b CI, confidence interval.

Table 4

Results of model-informed dosing regimens.

cWT ^a (kg)	PMA ^b (weeks)	SCR ^c (μmol/L)	Patients without VAS ^d (mg/kg)	Patients with VAS (mg/kg)
0.7–0.99	25–27	10	17.5–20, q24h	15–17.5, q24h
		25	15–17.5, q24h	15–17.5, q24h
		45	15–17.5, q24h	12.5–15, q24h
		60	15–17.5, q24h	12.5–15, q24h
		90	12.5–15, q24h	12.5–15, q24h
1.0–1.69	28–31	10	15–17.5, q18h	17.5–20, q24h
		25	12.5–15, q18h	17.5–20, q24h
		45	12.5–15, q18h	15–17.5, q24h
		60	12.5–15, q18h	15–17.5, q24h
		90	10–12.5, q18h	15–17.5, q24h
1.7–2.69	32–36	10	15–17.5, q12h	12.5–15, q12h
		25	12.5–15, q12h	10–12.5, q12h
		45	10–12.5, q12h	10–12.5, q12h
		60	10–12.5 q12h	10–12.5, q12h
		90	10–12.5, q12h	10, q12h
2.7–3.69	37–41	10	17.5–20, q12h	15–17.5, q12h
		25	15–17.5, q12h	12.5–15, q12h
		45	12.5–15, q12h	12.5–15, q12h
		60	12.5–15, q12h	12.5–15, q12h
		90	12.5–15, q12h	10–12.5, q12h
3.7 – 4.6	42–46	10	12.5–15, q8h	17.5–20, q12h
		25	12.5–15, q8h	15–17.5, q12h
		45	10–12.5, q8h	15, q12h
		60	10–12.5, q8h	15, q12h
		90	10, q8h	12.5–15, q12h

^a cWT, current body weight.

^b PMA, postmenstrual age.

^c SCR, serum creatinine.

^d VAS, vasoactive drugs, which are referred to milrinone, dopamine, epinephrine, and norepinephrine in our institution.